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Abstract
IjB kinase e (IKKe) is a key molecule at the crossroads of inflamma-
tion and cancer. Known to regulate cytokine secretion via NFjB and
IRF3, the kinase is also a breast cancer oncogene, overexpressed in a
variety of tumours. However, to what extent IKKe remodels cellular
metabolism is currently unknown. Here, we used metabolic tracer
analysis to show that IKKe orchestrates a complex metabolic repro-
gramming that affects mitochondrial metabolism and consequently
serine biosynthesis independently of its canonical signalling role. We
found that IKKe upregulates the serine biosynthesis pathway (SBP)
indirectly, by limiting glucose-derived pyruvate utilisation in the TCA
cycle, inhibiting oxidative phosphorylation. Inhibition of mitochon-
drial function induces activating transcription factor 4 (ATF4), which
in turn drives upregulation of the expression of SBP genes. Impor-
tantly, pharmacological reversal of the IKKe-induced metabolic
phenotype reduces proliferation of breast cancer cells. Finally, we
show that in a highly proliferative set of ER negative, basal breast
tumours, IKKe and PSAT1 are both overexpressed, corroborating the
link between IKKe and the SBP in the clinical context.
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Introduction
Chronic inflammation, triggered by the tumour stroma or driven by
oncogenes, plays a central role in tumour pathogenesis (Netea et al,
2017). A key step leading to inflammation in both compartments is
activation of the transcription factor nuclear factor jB (NFjB),
mediated via canonical or alternative, non-canonical pathways. Key
players in both pathways are the members of the IjB kinase (IKK)
family, which, by phosphorylating IjB, induce its proteasome-
mediated degradation, a step required for the release of NFjB from
its IjB-imposed cytosolic localisation, thus leading to its nuclear
translocation (Cle´ment et al, 2008).
Evidence in support of the crucial role played by the IKK family in
inflammation-induced malignant transformation was provided by the
reduction of tumour incidence following the deletion of the canonical
IKK family member IKKb in intestinal epithelial and myeloid cells in
a mouse model of colitis-associated cancer development (Greten
et al, 2004). Soon after, the non-canonical member of the IKK family,
IKKe, was shown to induce breast cancer (Boehm et al, 2007) and to
be overexpressed in ovarian (Guo et al, 2009), prostate (Pe´ant et al,
2011) and non-small cell lung cancers (Guo et al, 2013), pancreatic
ductal carcinoma (Cheng et al, 2011) and glioma (Guan et al, 2011).
In particular, IKKe was shown to induce breast cancer via mecha-
nisms involving CYLD (Hutti et al, 2009) and TRAF2 (Zhou et al,
2013), ultimately mediating NFjB activation (Boehm et al, 2007).
Beyond cancer, IKKe is a key regulator of both innate and adap-
tive immunity, activating NFjB and interferon regulatory factor 3
(IRF3), inducing type I interferon signalling (Cle´ment et al, 2008;
Zhang et al, 2016), although activation of the interferon response is
not essential for IKKe-mediated cellular transformation (Boehm
et al, 2007). On the other hand, IKKe has been shown to regulate
central carbon metabolism both in immune and cancer cells. In
dendritic cells (DCs), IKKe, together with its closest homologue
TANK binding kinase 1 (TBK1), is required for the switch to aerobic
glycolysis induced by activation of the Toll-like receptors (TLRs)
and activation of DCs. Glycolysis is the main glucose catabolic path-
way whereby, through a series of reactions, cells metabolise glucose
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to pyruvate which, in the presence of oxygen, is in turn oxidised to
CO2 in the mitochondrial matrix via the TCA cycle to produce ATP
using the mitochondrial respiratory chain. Lack of oxygen prevents
the mitochondrial utilisation of pyruvate, meaning glucose is instead
converted into lactate (anaerobic glycolysis). In contrast, aerobic
glycolysis refers to a metabolic condition whereby glucose is not
fully oxidised in the mitochondria, even in the presence of oxygen,
and is utilised for the production of amino acids, lipids and nucleo-
tides via pathways branching out from glycolysis and the TCA cycle.
Accordingly, aerobic glycolysis in DCs allows fatty acid synthesis,
which is required for the expansion of the endoplasmic reticulum
and Golgi, supporting DC activation (Everts et al, 2014). Allowing
the production of key cellular constituents, aerobic glycolysis is
most frequently observed in highly proliferative cells, such as acti-
vated immune cells and cancer cells (Andrejeva & Rathmell, 2017).
In agreement, IKKe also regulates glucose uptake in pancreatic
ductal adenocarcinoma and mitochondrial function in mouse
embryonic fibroblasts (MEFs) (Reilly et al, 2013; Zubair et al,
2016). In addition, we have recently demonstrated that IKKe and the
serine biosynthesis pathway (SBP) are important for the acquisition
of malignant traits in breast epithelium exposed to macrophage
conditioned medium and accordingly, expression of SBP enzymes
correlates with inflammation in breast cancer (Wilcz-Villega et al,
2020). Our findings are in line with the known function of the SBP
in cancer. Indeed, phosphoglycerate dehydrogenase (PHGDH), the
first enzyme of the pathway, is amplified in breast cancer and mela-
noma, where it functions as an oncogene (Locasale et al, 2011;
Possemato et al, 2011) and the SBP is also the target of a series of
oncogenes (Amelio et al, 2014; Yang & Vousden, 2016). However, a
comprehensive investigation of the role of IKKe as regulator of cellu-
lar metabolism in cancer has not yet been carried out. Taking an
unbiased approach, we followed the fate of C13 glucose upon modu-
lation of IKKe expression. We found that IKKe inhibits the mitochon-
dria and indirectly controls the SBP via activation of ATF4,
ultimately driving the upregulation of the SBP enzymes, in particu-
lar phosphoserine aminotransferase 1 (PSAT1). Importantly, we also
demonstrate that IKKe-mediated regulation of cellular metabolism is
independent of the canonical signalling pathway via NFjB/IRF3.
Moreover, we have identified a subset of basal, estrogen receptor
negative (ER) highly proliferative breast tumours where IKKe and
PSAT1 are both overexpressed, confirming the pathophysiological
role of our findings. These results identify an additional role for
IKKe in breast cancer, adding regulation of cellular metabolism to
the canonical oncogenic mechanisms. Thus, our data suggest a
synergistic mechanism of action by which alterations of cellular
metabolism and inflammation driven by the IKKe oncogene support
tumour growth and proliferation.
Results
IKKe rewires cellular metabolism
To investigate the effect of IKKe activation on metabolism, we used
two cellular model systems: (i) doxycycline-inducible Flp-In 293 HA-
IKKe-expressing cells and their respective GFP-expressing controls
(Flp-In 293 HA-GFP cells) and (ii) two breast cancer cell lines, T47D
and MDA-MB-468, where the kinase was silenced via siRNA. HEK-
293 cells do not express endogenous IKKe, and thus, we could set its
expression to a level that matched those observed in IKKe expressing
breast cancer cell lines (Boehm et al, 2007) (Fig 1A). Liquid chro-
matography–mass spectrometry (LC–MS) analysis of steady-state
metabolite levels revealed that induction of IKKe expression affected
a large fraction of the measured metabolites (26 out of 32, Fig 1B
and Dataset EV1). To account for any possible effect of doxycycline
on cell metabolism, we compared cells with doxycycline-induced
expression of IKKe versus GFP (Ahler et al, 2013). Of particular
interest, IKKe increased cellular glucose and glutamine levels, along
with a group of amino acids, including serine and glycine. The
increased intracellular level of serine was likely a consequence of
increased biosynthesis as we observed a significant increase in the
level of 13C6-glucose-derived serine (m + 3 isotopologue), suggesting
that IKKe positively regulates the SBP (Fig 1C). A key enzyme in the
SBP is phosphoserine aminotransferase 1 (PSAT1), which transfers
nitrogen from glutamine-derived glutamate to phosphohydroxypyru-
vate, generating phosphoserine for the final dephosphorylation step
of serine biosynthesis (Fig 1D). Using 15N2-glutamine labelling, we
confirmed increased levels of labelled serine (m + 1) in IKKe
expressing cells (see Fig 1C and Dataset EV1), consistent with an
increase in PSAT1 transamination activity, supporting our hypothe-
sis that serine biosynthesis was activated by IKKe. In contrast, we
observed a significant reduction in the accumulation of the TCA
cycle intermediates citrate m + 2 and malate m + 2 from 13C6-glucose,
indicating that IKKe reduces pyruvate dehydrogenase (PDH) activity
(Fig 1E). Fractional enrichment analysis of the above metabolites
showed that in addition to increased serine biosynthesis, IKKe also
augmented serine uptake from the media, shown by an increase in
serine m + 0 isotopologue (Fig 1F). Moreover, the fraction of 13C6-
glucose-derived citrate and malate (m + 2, pyruvate dehydrogenase
generated) was reduced in IKKe expressing cells, causing reduction in
their total levels, indicating that no other carbon sources (e.g. gluta-
mine) compensate for the lack of pyruvate entering the TCA cycle
(Fig 1F). Finally, the fraction of 15N labelled serine derived from gluta-
mine was also increased, indicating higher glutamine usage in serine
biosynthesis as nitrogen source (Fig 1G).
We then investigated whether IKKe has a similar metabolic func-
tion in breast cancer cell lines, where it is constitutively expressed.
Since IKKe has been shown to be an oncogene in different breast
cancer subtypes (Boehm et al, 2007), we used T47D and MDA-MB-
468 cell lines to model estrogen receptor positive (ER+) and triple-
negative breast cancer, respectively (Subik et al, 2010). After
silencing the kinase (Fig 2A and B), 13C6-glucose and
15N2-glutamine
labelling analysis confirmed the overall effect of IKKe on cellular
metabolism. In the serine and glycine biosynthesis pathways, IKKe
silencing exerted the opposite effect as compared to IKKe induction
in the Flp-In 293 model (Fig 2C–F and Dataset EV1). Similarly, IKKe
knockdown resulted in increased levels of the TCA cycle metabolites
citrate and malate m + 2 isotopologues, derived from 13C-glucose via
PDH (Fig 2E and F). Taken together, these data indicated that in
cancer cells IKKe redirects a significant fraction of glucose-derived
carbons to the SBP and reduces pyruvate oxidation in the TCA cycle.
IKKe inhibits mitochondrial function via PDH
Considering the effect on the TCA cycle observed via tracer
compounds (see Figs 1 and 2), we assumed that IKKe alters
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mitochondrial oxidative function. Indeed, mitochondrial oxygen
consumption rate (OCR) was suppressed by IKKe induction in the
Flp-In 293 HA-IKKe cell line, accompanied by reduced mitochondrial
membrane potential (Dwm), as assessed by respirometry and steady-
state tetramethyl-rhodamine methylester (TMRM) intensity imaging.
Of note, when using Flp-In 293 cells that express mutant variants of
HA-IKKe, which feature mutations disrupting the function of IKKe’s
kinase domain (KD-m) and Ubiquitin-like domain (UbLD-m), we
confirmed that both functional domains of the kinase (Ikeda et al,
2007) were required to exert inhibition of mitochondria (Fig 3A and
B). Furthermore, IKKe silencing resulted in significantly higher OCR
in a set of breast cancer cells (Figs 3C and EV1A). IKKe primarily
affected ATP-coupled respiration, without significantly inhibiting
uncoupled or reserve OCR, as shown by measuring respiration in
the presence of oligomycin (inhibitor of the ATP synthase), and the
uncoupler FCCP, respectively (Fig EV1B–F). Moreover, the effect
was integral to the mitochondria, since mitochondria isolated from
IKKe expressing cells showed reduced respiration compared to those
isolated from GFP-expressing controls (Fig 3D).
In order to elucidate the mechanism by which IKKe regulates
mitochondrial metabolism, we compared the phosphoproteomes of
three independent control (GFP) and IKKe expressing Flp-In 293
clones. Multivariate analysis showed that the two clones highly
expressing IKKe grouped together in principal component analysis
(PCA) and were separated from controls and cells expressing IKKe
at low levels (Fig 3E and F). These results suggested that IKKe
induces a dose-dependent effect in the phosphoproteome of these
cells. We identified more than 3,000 phosphopeptides quantified in
four technical replicates, which interestingly included the E1
subunit of the pyruvate dehydrogenase complex (PDHA1 - pS232)
(Dataset EV2).
Phosphorylation of PDHA1 on S232 is known to inhibit PDH
activity and is also reported to be necessary for tumour growth
(Golias et al, 2016), and thus, we hypothesised that IKKe regulates
pyruvate entry in the TCA cycle and consequently electron provi-
sion for the respiratory chain. Of note, other phosphosites of PDHA1
were either unchanged or less phosphorylated, indicating that the
increase in pS232 is not due to higher level of expression of the
protein (Dataset EV2). In agreement with our hypothesis, PDH activ-
ity was reduced in IKKe expressing cells (Fig 3G), and the effect was
reverted by inhibiting pyruvate dehydrogenase kinase using dichlor-
oacetic acid (DCA) (Stacpoole, 1989). DCA restored both IKKe-
mediated reduction of Dwm and inhibition of respiration in Flp-In
293 mitochondria, but had no effect in control cells (Fig 3H and I),
indicating that diminished pyruvate oxidation by the PDH complex
is the limiting factor of respiratory activity in IKKe overexpressing
◀ Figure 1. IKKe induces remodelling of cellular carbon metabolism by activating the serine biosynthesis pathway (SBP) and suppressing pyruvate oxidation.
A Top panel: Scheme illustrating the tetracycline-inducible Flp-In 293 system that controls the expression of HA-IKKe or HA-GFP. Bottom panel: Representative Western
blot showing induced expression of HA-IKKe in Flp-In 293 cells treated with doxycycline (Dox, 50 ng/ml) for 16 h compared to endogenous IKKe in T47D, MDA-MB-231
and MDA-MB-468 breast cancer cell lines.
B Heatmap and hierarchical clustering of metabolite concentrations in Flp-In 293 HA-GFP and Flp-In 293 HA-IKKe cells treated with doxycycline (Dox, 50 ng/ml, 16 h;
n = 5 technical replicates).
C Serine production from glucose (serine m + 3, 13C6-glucose labelling, left panel) and glutamine (serine m + 1,
15N2-glutamine labelling, right panel) in Flp-In 293
HA-GFP or Flp-In 293 HA-IKKe cells treated with doxycycline (50 ng/ml, 16 h; n = 5 technical replicates).
D Schematic representation of the 13C6-glucose and
15N2-glutamine labelling strategy to assess the effect of HA-IKKe induction on glycolysis, the TCA cycle and serine
metabolism.
E Contribution of pyruvate and glucose-derived carbon to TCA cycle metabolites in Flp-In 293 HA-GFP or Flp-In 293 HA-IKKe cells treated with doxycycline (50 ng/ml,
16 h; n = 5 technical replicates).
F Fractional enrichment of serine, malate and citrate 13C-isotopologues in Flp-In 293 HA-GFP and Flp-In 293 HA-IKKe cells treated with doxycycline (50 ng/ml, 16 h;
n = 5 technical replicates).
G Fractional enrichment of the serine 15-N-isotopologue in Flp-In 293 HA-GFP and Flp-In 293 HA-IKKe cells treated with doxycycline (50 ng/ml, 16 h). m + 1 shows the
naturally occurring 13C isotopologue (n = 5 technical replicates).
Data Information: In (C, E–G), metabolite levels were normalised to the internal standard HEPES. In (C) and (E–G), data are presented as mean  SD, *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001 (two-tailed Student’s t-test or Mann–Whitney test).
Source data are available online for this figure.
▸Figure 2. The effect of IKKe silencing on metabolism of breast cancer cell lines.A, B Representative Western blot showing the level of IKKe in IKBKE (IKKe)-silenced (A) T47D and (B) MDA-MB-468 breast cancer cell lines.
C, D Heatmap and hierarchical clustering of metabolite concentrations in (C) IKBKE (IKKe)-silenced T47D cells and (D) IKBKE (IKKe)-silenced MDA-MB-468 cells
(n = 5 technical replicates).
E Glycine production, representative of serine production, from glutamine (glycine m + 1, 15N2-glutamine labelling) and glucose (glycine m + 2,
13C6-glucose
labelling), and contribution of pyruvate and glucose-derived carbon to TCA cycle metabolites (citrate m + 2, malate m + 2, 13C6-glucose labelling) in IKBKE (IKKe)-
silenced T47D cells. (n = 5 technical replicates).
F Serine production from glutamine (serine m + 1, 15N2-glutamine labelling), and serine and glycine production from glucose (glycine m + 2, serine m + 3,
13C6-glucose labelling) as well as contribution of pyruvate and glucose-derived carbon to TCA cycle metabolites (malate m + 2,
13C6-glucose labelling) in IKBKE
(IKKe)-silenced MDA-MB-468 cells. (n = 5 technical replicates).
Data Information: In (C, E), metabolite levels were normalised to the internal standard HEPES. In (D, F), metabolite levels were normalised to total ion count. In (C, D),
metabolite levels were scaled to maximum and minimum levels of each metabolite. In (E, F), data are presented as mean  SD, *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001 (two-tailed Student’s t-test).
Source data are available online for this figure.
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cells. In line with this conclusion, we also showed that IKKe overex-
pressing cells rely less on pyruvate for their respiration in compar-
ison with control cells, expressing GFP (Fig 3J).
IKKe activates the SBP transcriptional response via ATF4
Our tracer experiments indicated that in addition to inhibiting
mitochondria, IKKe also stimulated serine biosynthesis (Figs 1 and
2). Since mitochondrial dysfunction has previously been shown to
induce activation of activating transcription factor 4 (ATF4) and to
regulate SBP gene transcription (Bao et al, 2016; Khan et al, 2017),
we hypothesised that IKKe-induced mitochondrial inhibition elicits
a similar ATF4-mediated response, in turn inducing serine biosyn-
thesis. Confirming this hypothesis, ATF4 was induced in IKKe
expressing cells (Fig 4A), while c-Myc, another known regulator of
serine metabolism (Nikiforov et al, 2002; Sun et al, 2015; Anderton
et al, 2017), remained unchanged (Fig EV2A). We therefore
assessed the overall level of the three enzymes of the pathway:
PHGDH, PSAT1 and phosphoserine phosphatase (PSPH). We
observed that IKKe induction in Flp-In 293 HA-IKKe cells led to a
marked (2–6 fold) increase in the transcription of all three SBP
enzyme mRNAs (Fig 4B), which was also reflected at the protein
level (with the exception of PHGDH). Of note, consistently with
the role of IKKe as key mediator of the innate immune response,
IRF3 was also phosphorylated upon induction of the kinase, con-
firming the activation of canonical kinase signalling in addition to
the upregulation of ATF4 and SBP enzymes (Fig 4C). Importantly,
silencing of ATF4 abolished the transcriptional upregulation of SBP
enzymes mediated by IKKe and reduced their protein levels
(Fig 4D and E), demonstrating the requirement of the transcription
factor for the upregulation of SBP enzymes by the kinase.
Moreover, while the enzymes of the SBP were upregulated in Flp-
In 293 HA-IKKe cells, we did not observe differences in the level of
expression of serine hydroxymethyltransferase 2 (SHMT2), the
main mitochondrial enzyme involved in serine catabolism (Stover
& Schirch, 1990), supporting the hypothesis that IKKe primarily
acts on serine biosynthesis. The lack of changes in SHMT2
expression is also in agreement with the lack of c-Myc involve-
ment in the IKKe-induced pathway (Fig EV2B, and see (Nikiforov
et al, 2002)).
Confirming the role of IKKe/ATF4 observed in our HEK model
cell line, silencing of IKKe in a panel of breast cancer cell lines had
the opposite effect. Upon siRNA-mediated knockdown of IKKe,
downregulation of PSAT1 at the transcriptional level was observed
in 5 out of 9 breast cancer cell lines tested (ZR-75-1, T47D, MDA-
MB-468, Cal120 and HCC1143) (Fig 5A). Downregulation at the
protein level was also observed in all cell lines where the protein
was detected (with the exception of MDA-MB-231). At the protein
level, we also observed downregulation of PHGDH in ZR-75-1,
MDA-MB-468 and MCF7 cells and of PSPH in ZR-75-1, MDA-MB-
453 and MDA-MB-468 cells (Fig 5B–E), while no increase in SHMT2
was observed (Fig EV2C and D). Moreover, reduction of the SBP
enzymes was also observed in breast cancer cell lines upon the
silencing of ATF4 (Fig 5F and G), in agreement with previous data
(DeNicola et al, 2015).
Altogether, these data indicated that IKKe orchestrates a complex
metabolic reprogramming that encompasses the inactivation of
mitochondrial metabolism and the consequent transcriptional acti-
vation of the SBP, mediated by ATF4.
Importantly, siRNA of PSAT1 in Flp-In 293 HA-IKKe or in the
breast cancer cell lines panel had no effect on oxygen consump-
tion, further supporting that IKKe-mediated regulation of the SBP
is a secondary event to regulation of the mitochondria (Fig EV3A
and B).
IKKe induces SBP gene transcription via a
non-canonical mechanism
Next, we tested the involvement of the canonical downstream
signalling pathways known to be activated by the kinase. Silenc-
ing of the transcription factors IRF3 and p65 (Cle´ment et al, 2008)
did not abolish the induction of SBP enzyme gene transcription by
◀ Figure 3. IKKe inhibits mitochondrial metabolism via reducing PDH activity.A Basal oxygen consumption in Flp-In 293 HA-IKKe wt, Flp-In 293 HA-IKKe KD-m and Flp-In 293 HA-IKKe UbLD-m cells following treatment with doxycycline (Dox, 16 h),
measured using Oroboros high-resolution respirometry. Data are normalised to non-treated control cells.
B Average TMRM staining intensity in Flp-In 293 HA-IKKe wt, Flp-In 293 HA-IKKe KD-m and Flp-In 293 HA-IKKe UbLD-m expressing cells induced by doxycycline (Dox,
16 h). Data are normalised to non-treated control cells.
C Basal mitochondrial oxygen consumption rate (OCR) in a panel of IKBKE (IKKe)-silenced breast cancer cell lines, measured using Seahorse XF96e or XF24 analysis.
D OCR in mitochondria isolated from Flp-In 293 HA-GFP or HA-IKKe cells treated with doxycycline (50 ng/ml, 16 h), measured using Oroboros high-resolution
respirometry.
E Principal component analysis of differentially phosphorylated substrates in three independent single cell clones of Flp-In 293 HA-GFP or Flp-In 293 HA-IKKe cells
treated with doxycycline (100 ng/ml, 16 h). The phosphoproteomes in the three clones were analysed by mass spectrometry as described in material and methods.
F Representative Western blot showing level of IKKe in three independent single cell clones of Flp-In 293 HA-GFP or Flp-In 293 HA-IKKe cells following treatment with
doxycycline (100 ng/ml, 16 h).
G Relative pyruvate dehydrogenase (PDH) activity in Flp-In 293 HA-GFP or Flp-In 293 HA-IKKe cells treated with doxycycline (50 ng/ml, 16 h).
H Average TMRM staining intensity in Flp-In 293 HA-GFP or Flp-In 293 HA-IKKe cells treated with doxycycline (Dox) and dichloroacetate (DCA) (both for 16 h). Data are
normalised to non-treated Flp-In 293 HA-IKKe cells.
I Basal OCR in Flp-In 293 HA-GFP or Flp-In 293 HA-IKKe cells treated with doxycycline (50 ng/ml) in combination with DCA for 16 h, measured using Oroboros high-
resolution respirometry.
J Basal OCR in Flp-In 293 HA-GFP or Flp-In 293 HA-IKKe cells treated with doxycycline (50 ng/ml) in combination with pyruvate deprivation for 16 h, measured using
Oroboros high-resolution respirometry.
Data Information: All data are n ≥ 3 biological replicates, with the exception of (E) which is n = 4 technical replicates. Data are presented as mean  SEM, *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001. In (C, G), data were normalised to total sample protein concentration. The following statistical tests were applied: in (A, B) two-
way ANOVA with Fisher’s LSD post hoc tests, in (C, D, G) two-tailed paired Student’s t-tests, in (H, I) one-way ANOVA with Fisher’s LSD post hoc tests and in (J) one-way
ANOVA with Tukey’s multiple comparison tests.
Source data are available online for this figure.
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IKKe (Fig EV3C–E). Of note, these experiments indicated that IRF3
is required to maintain the transcription of PHGDH in basal condi-
tions, but has no role in IKKe-mediated induction. Finally, since
IKKe induces the secretion of a range of cytokines (Barbie et al,
2014), we tested the possibility that the induction of SBP enzyme
gene transcription is mediated by an autocrine loop. Extracellular
media conditioned by HA-GFP or HA-IKKe expressing Flp-In 293
cells was collected and applied on three different receiving cell
lines: Flp-In 293 HA-GFP, not expressing IKKe (Fig EV4A) and
the T47D and ZR-75-1 breast cancer cell lines, constitutively
expressing IKKe (Fig EV4B and C). Media conditioned by IKKe
expressing cells had no effect on the SBP enzymes, even though
cytokine-mediated JAK-STAT signalling was observed in all three
receiving cell lines, as demonstrated by induction of STAT1,
phospho-STAT1 and OAS1 (an interferon-inducible gene, only in
ZR-75-1).
Altogether, these results demonstrated that IKKe induces SBP
enzyme gene transcription by a cell-autonomous mechanism which,
however, does not include its canonical downstream targets.
Pharmacological inhibition of IKKe-induced metabolic changes
reduces cell proliferation
To test the functional consequences of the IKKe-mediated meta-
bolic rewiring on tumour proliferation, we assessed the outcome
of inhibiting the two key metabolic reactions of serine biosynthe-
sis on cell proliferation in a panel of breast cancer cell lines.
Significantly reduced breast cancer cell proliferation was observed
upon treatment with NCT502, a recently described inhibitor of the
SBP (Pacold et al, 2016), in four out of the eight cell lines tested
(ZR-75-1, T47D, MDA-MB-468 and HCC1143), while its PHGDH
inactive form only had an effect in T47D cells (Fig EV5A). Impor-
tantly, the effect on proliferation was significantly correlated with
the effect of IKKe on mitochondrial OCR, but not extracellular
acidification rate (Figs 6A and EV5B). These results suggested that
inhibition of the specific metabolic effect regulated by IKKe corre-
lates with cancer cell proliferation rate. The same effect was
observed upon treatment with the glutamine antagonist 6-diazo-5-
oxo-l-norleucine (DON) (Cervantes-Madrid et al, 2015) and CB839
(Gross et al, 2014), to inhibit glutaminase and thus glutamate
availability for PSAT1 (Figs 6B and EV5C–E). These results
suggest that IKKe-induced metabolic changes promote cell prolifer-
ation and might be valuable targets to inhibit IKKe-driven tumori-
genesis.
IKKe and PSAT1 are overexpressed in a common, highly
proliferative subset of breast cancer
In order to explore IKKe and SBP enzyme gene expression status
in breast cancer patient samples, we analysed the METABRIC
dataset (Curtis et al, 2012), which includes data from 1981 breast
cancer patients with pathological and clinical details. IKBKE and
PSAT1 mRNA were significantly upregulated (above the 95% con-
fidence interval) in 200 (10.1%) and 664 (33.5%) samples,
respectively, and 107 (5.4%) samples showed overexpression of
both mRNAs. This indicated a highly significant association
between the two genes, as confirmed chi-square independence test
(Fig 6C). Given that breast cancer is a heterogenous disease,
commonly classified into 5 to 10 intrinsic subtypes (Perou et al,
2000; Curtis et al, 2012), the association of IKBKE and PSAT1
might be driven by subtype-specific expression. Thus, in order to
identify subtypes with significant overexpression compared to the
total population, we compared the expression values of IKBKE
and the SBP genes in all Pam50 subtypes (Parker et al, 2009;
Jiang et al, 2016) and in the estrogen receptor (ER) positive and
negative populations. This analysis indicated that both IKBKE and
PSAT1, similarly to PHGDH and PSPH, are significantly upregu-
lated in an ER-negative Pam50:basal subpopulation of tumours,
with the highest proliferation index (Nielsen et al, 2010) (Fig 6D–
H). ATF4-driven overexpression of PSAT1 in ER-negative tumours
has been previously shown in a different dataset (Gao et al, 2017)
and here we also have found strong association of these two
genes (Fig 6I and J). Importantly, while PSAT1 is overexpressed
in almost all ER-negative samples (378 out of 435), only 79
samples overexpress IKBKE, indicating that PSAT1 is regulated by
multiple inputs. However, above 90% of samples overexpressing
IKBKE (72 out of 79) also overexpress PSAT1. Due to the large
fraction of PSAT1 overexpressing samples in the ER-negative
subset and the overall low expression and detected variability of
IKBKE and ATF4 mRNAs in the dataset, only low but still statisti-
cally significant levels of correlation could be found between these
genes (Fig 6K and L). However, these gene expression patterns
clearly show that IKKe-mediated expression of PSAT1 and the SBP
enzymes, demonstrated in our in vitro experiments, is potentially
also functional in a subset of clinical samples, suggesting the
pathophysiological importance of the pathway in breast cancer.
Importantly, we also confirmed the correlation between IKKe and
PSAT1 expression in a set of breast cancer cases (Wilcz-Villega
et al, 2020).
◀ Figure 4. IKKe stimulates SBP enzyme gene transcription via ATF4.A Representative Western blot showing the level of ATF4 in ATF4-silenced Flp-In 293 HA-IKKe cells treated with doxycycline (Dox) for 16 h.
B qRT–PCR analysis of PHGDH, PSAT1 and PSPH mRNA levels in Flp-In 293 HA-GFP or Flp-In 293 HA-IKKe cells treated with doxycycline (Dox) for 16 h. Data are
expressed as fold changes, relative to levels in non-treated Flp-In 293 HA-GFP cells and normalised to b-Actin (n = 4 biological replicates)
C Representative Western blot showing levels of IKKe, IRF3, phosphorylated IRF3 (S396) and SBP enzymes in Flp-In 293 HA-GFP or Flp-In 293 HA-IKKe cells treated with
doxycycline (Dox) for 16 h.
D qRT–PCR analysis of PHGDH, PSAT1 and PSPH mRNA levels in ATF4-silenced Flp-In 293 HA-IKKe cells treated with doxycycline (Dox) for 16 h. Data are expressed as fold
changes, relative to levels in a non-silenced, non-treated control and normalised to b-Actin (n = 5 biological replicates).
E Representative Western blot showing the levels of IKKe, PHGDH, PSAT1 and PSPH in ATF4-silenced Flp-In 293 HA-IKKe cells treated with doxycycline (Dox) for 16 h.
Data Information: In (B, D), data are presented as mean  SEM, statistics were performed using log-transformed fold change values. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001, measured using two-way ANOVA with Bonferroni post hoc tests.
Source data are available online for this figure.
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Discussion
Here, we described a novel fundamental mechanism by which IKKe,
a key player in the innate immune response, regulates cellular meta-
bolism. We show that the kinase orchestrates a complex metabolic
reprogramming culminating in the regulation of the serine biosyn-
thesis pathway. The mechanism involved in IKKe-mediated regula-
tion of the SBP is inhibition of carbon supply to the mitochondria,
leading to the transcriptional upregulation of SBP genes via a mito-
chondrial-nuclear retrograde signalling pathway targeting ATF4,
ultimately activating serine biosynthesis. The overall metabolic
switch induced by IKKe supports cancer cell proliferation and is
present in a subset of breast tumours, providing potentially impor-
tant pharmacological targets. The pathway described here is remi-
niscent of recent data showing that the uptake of pyruvate in
mitochondria regulates the SBP (Baksh et al, 2020).
While such mechanistic details of the function of IKKe as a newly
identified modulator of the SBP and mitochondria have not been
reported before, previous studies implicated IKKe in the regulation
of cellular metabolism. Consistent with our data, IKKe was shown
to inhibit OCR in MEFs (Reilly et al, 2013) and regulate glycolysis in
DCs, although in this system the kinase did not affect mitochondrial
metabolism (Everts et al, 2014). Similarly, in pancreatic ductal
adenocarcinoma, IKKe was shown to stimulate glucose uptake, but
did not inhibit mitochondrial respiration (Zubair et al, 2016). Thus,
IKKe appears to modulate cellular metabolism in a tissue- and
context-specific manner, and our study pinpoints and extends the
breadth of the specific cellular targets utilised by the kinase to exert
these heterogeneous responses. Importantly, in addition to the
previously known canonical NFjB and IRF3 signalling pathways
(Cle´ment et al, 2008), IKKe can engage the mitochondrial-nuclear
ATF4-mediated signalling. Whether NRF2, previously demonstrated
to regulate the SBP upstream of ATF4 (DeNicola et al, 2015), is also
involved in the signalling induced by IKKe, remains to be tested.
While here we have shown that in breast cancer cells IKKe-mediated
changes in metabolism support proliferation, these metabolic alter-
ations might also facilitate other cellular functions (Jones & Bianchi,
2015), for example, cytokine secretion in immune cells (Chang et al,
2013; Tannahill et al, 2013; Rodriguez et al, 2019; Yu et al, 2019).
Apart from providing novel mechanistic details of IKKe-mediated
cellular metabolic changes, this work also indicates the necessity of
further research to better understand the physiological and patho-
logical role of IKKe in order to efficiently and selectively target
tumour cells relying on this oncogene. Our observations suggest that
drugs targeting IKKe-regulated metabolic pathways can specifically
target breast cancer cells without affecting other cell types, consider-
ing that it is only in these cells that IKKe has been reported to regu-
late the SBP. Indeed, our gene expression analysis indicated that the
IKKe-mediated pathway defines a subset of ER, basal breast
tumours, and thus, evaluation of the IKKe-mediated metabolic and
gene expression phenotype can help to further stratify breast cancer
for treatment. Our stratification is also in agreement with previous
◀ Figure 5. The SBP is primarily regulated by an IKKe-mediated transcriptional response.A qRT–PCR analysis of PHGDH, PSAT1 and PSPH mRNA levels in a panel of IKBKE (IKKe)-silenced breast cancer cell lines. Data are expressed as fold changes, relative to
levels in a non-silenced control of each cell line and normalised to b-Actin (n ≥ 3 biological replicates).
B Representative Western blot showing the levels of IKKe and the SBP enzymes in IKBKE (IKKe)-silenced ZR-75-1, T47D, MDA-MB-468 and MCF7 breast cancer cell
lines.
C–E Levels of the SBP enzymes in a panel of IKBKE (IKKe)-silenced breast cancer cell lines. (C) PHGDH, (D) PSAT1 and (E) PSPH levels in indicated cell lines normalised to
Vinculin. Densitometry analysis quantified single sample density as a percentage of total blot density per cell line prior to vinculin normalisation (n ≥ 3 biological
replicates).
F qRT–PCR analysis of PHGDH, PSAT1 and PSPH mRNA levels in ATF4-silenced ZR-75-1, T47D and MDA-MB-468 breast cancer cell lines. Data are expressed as fold
changes, relative to levels in non-silenced control cells and normalised to b-Actin (n = 3 biological replicates).
G Representative Western blot showing the levels of PHGDH, PSAT1 and PSPH in ATF4-silenced ZR-75-1, MDA-MB-468, MDA-MB-231, T47D and HCC1143 breast
cancer cell lines.
Data Information: In (A, C–F), data are presented as mean  SEM. *P < 0.05, **P < 0.01, ***P < 0.001. In (A, F), one-sample t-tests were performed using
log-transformed fold change values for all samples, except Sum44 PHGDH in (A), in which case a Wilcoxon signed rank was performed using log-transformed fold
change values. In (C–E), two-tailed paired t-tests were performed.
Source data are available online for this figure.
▸Figure 6. The pathophysiological role of IKKe-induced metabolic and gene expression alterations in breast cancer.A Correlation of change in OCR (DOCR) in a panel of IKBKE (IKKe)-silenced breast cancer cell lines (from Fig 3C) and the change in cell confluency (Dconfluency) upon
treatment of the panel of cell lines with NCT502 (from Fig EV5A).
B Correlation of DOCR in a panel of IKBKE (IKKe)-silenced breast cancer cell lines (from Fig 3C) and the Dconfluency upon treatment of the panel of cell lines with
6-Diazo-5-oxo-L-norleucine (DON) (from Fig EV5C).
C Association between IKBKE (IKKe) and PSAT1 mRNA overexpression evaluated by a chi-squared independence test. The + sign indicates samples with significant
(P < 0.05) overexpression of IKBKE or PSAT1. Number and percentage of samples, as well as the chi-square values are shown.
D–I Expression of IKBKE (IKKe) and the SBP enzymes PSAT1, PHGDH and PSPH in the METABRIC dataset. The expression of a proliferation-related gene set and ATF4 is
also shown. Samples were stratified by Pam50 intrinsic subtypes and ER status. Brown–Forsythe and Welch ANOVA test with unpaired t with Welch correction
were applied. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
J Association between ATF4 and PSAT1 mRNA overexpression evaluated by chi-squared independence test. The + sign indicates samples with significant (P < 0.05)
overexpression of ATF4 or PSAT1. Number and percentage of samples, as well as the chi-square values are shown.
K, L Correlation of IKBKE (IKKe) and PSAT1 (K) or ATF4 and PSAT1 (L) expression in the ER-negative sample subset.
Data Information: In (A, B), cell confluency was measured using the IncuCyte Zoom, DOCR was measured using Seahorse XF96e or XF24 analysis. Data are n ≥ 3
biological replicates. In (A, B, K, L) linear regression, correlation coefficients (Pearson’s correlation, Spearman’s rho) significance of difference from slope = 0 are shown.
Source data are available online for this figure.
ª 2020 The Authors EMBO reports 21: e48260 | 2020 11 of 18
Ruoyan Xu et al EMBO reports
AC D E
J K L
F G H I
B
Figure 6.
12 of 18 EMBO reports 21: e48260 | 2020 ª 2020 The Authors
EMBO reports Ruoyan Xu et al
studies, where strong correlation between PSAT1 expression and
tumour proliferation has been found in ER tumours (Coloff et al,
2016; Gao et al, 2017). Of note, IKKe, along with the JAK/STAT
pathway, has been reported to regulate a cytokine network promot-
ing cellular proliferation in a subset of triple-negative breast
tumours (Barbie et al, 2014), and PSAT1 overexpression is also a
feature of a small fraction of ER+ tumours along with the JAK-STAT
pathway (De Marchi et al, 2017). While we have shown that IKKe
activates the JAK-STAT pathway (Fig EV4) along with PSAT1 over-
expression, JAK-STAT activation per se was not sufficient for the
induction of the enzyme. This indicates that both IKKe and PSAT1
are defining features in order to identify tumours where the pathway
is actively promoting proliferation.
Finally, further work is required to investigate whether the IKKe-
mediated metabolic phenotype described here, especially regarding
the regulation of the SBP, occurs in different cellular systems where
IKKe is known to be activated. This could help to develop new ther-
apeutic strategies applicable in a broad range of inflammation-
related diseases, beyond cancer.
Materials and Methods
Plasmids
DNA fragments encoding wild-type human IKKɛ (UniProt: Q14164)
were amplified separately by PCR using primers containing Kpn1
(50) and EcoR1 (30) restriction sites.
For 50-ttggtaccagccagctcagggcaggagatgcagagcacagccaatta-30
Rev 50-gatggatatctgcagaattcaggaggtgctgggactc-30
The PCR products were double digested by these two enzymes
and ligated to vector pcDNA5.5 (a kind gift from Dr Tencho Tenev),
which provides a 2xHA tag at the c-terminal, to generate the
pcDNA5.5-wt-IKKe plasmid. For mutant variants of IKKe with
disrupted functional domains, the kinase domain mutant (KD-m)
was created by site-directed mutagenesis, using primers to introduce
a K38A mutation to the wild-type IKKe sequence.
For 50-gagctggttgctgtggcggtcttcaacactac-30
Rev 50-gtagtgttgaagaccgccacagcaaccagc-30
UbLD-M-IKKɛ plasmid, encoding the ubiquitin-like domain
mutant (UbLD-m) variant of IKKe (containing L353A and F354A
mutations) was a kind gift from Prof Ivan Dikic. Both KD-m and
UbLD-m IKKe variants were amplified and ligated into the pcDNA5.5
vector using the same Kpn1 and EcoR1 double digestion and ligation
method as the wild-type kinase, generating the pcDNA5.5-KD-M-
IKKe and pcDNA5.5-UbLD-M-IKKe plasmids.
Cells
To generate Flp-In 293 cells expressing either wild type, kinase
domain mutant (KD-m) or ubiquitin-like domain mutant (UbLD-m)
IKKe, Flp-In 293 cells (Invitrogen) were transfected with either
pcDNA5.5-wt-IKKɛ, pcDNA5.5-KD-M-IKKɛ (K38A), pcDNA5.5-UbLD-
M-IKKɛ (L353A F354A) or pcDNA5.5-GFP, together with a pOG44
plasmid at a molar ratio of 1:9. cDNA plasmids were mixed with
Lipofectamine LTX (15338100, Thermo Fisher Scientific) or Fugene
HD (E2311, Promega) according to the manufacturer’s instruction
and transfected into the different cell lines for 48 h.
Stable cell lines and single cell clones expressing wild-type IKKe
(wt) or mutant IKKe, with disruption of either kinase domain or
ubiquitin-like domain function (KD-m or UbLD-m), in a doxycycline-
dependent manner were selected with 300 lg/ml hygromycin (Cal-
biochem). All Flp-In 293 cells were cultured in DMEM
(Sigma-Aldrich). The panel of breast cancer cell lines were kindly
provided by Dr. Alice Shia and Prof. Peter Schmid. MDA-MB-231,
MDA-MB-468, MDA-MB-175, ZR75.1, T47D, HCC1143, MCF7 were
cultured in RPMI-1640 (Sigma-Aldrich), Cal120 and MDA-MB-453
were cultured in DMEM (Sigma-Aldrich) and Sum44 in DMEM
(Sigma-Aldrich) and 1 nM estrogen (Sigma-Aldrich). For all cell
lines, medium was supplemented with 10% FBS, penicillin–strepto-
mycin and Normocin (InvivoGeN). Serine-free medium was custom
made DMEM without serine, with 10% dialysed FBS and penicillin–
streptomycin. All cells were cultured with environmental conditions
of 37°C, 5% CO2.
Drugs
The following drugs were used: 6-Diazo-5-oxo-L-norleucine (Don,
D2141, Sigma-Aldrich); Sodium dichloroacetate (DCA, 347795,
Sigma-Aldrich); NCT-502 and PHGDH inactive (19716 and 19717,
Cayman); Doxycycline (Dox, D9891, Sigma-Aldrich), Oligomycin
(sc-203342, Santa Cruz Biotechnology); FCCP (sc-203578, Santa
Cruz Biotechnology); Antimycin (sc-202467, Santa Cruz Biotechnol-
ogy); Rotenone (sc-203242, Santa Cruz Biotechnology); Cyt.C
(C2037, Sigma-Aldrich) CB-839 (10-4556, Focus Biomolecules);
Adenosine diphosphate (ADP, A2754, Sigma-Aldrich).
siRNA transfection
The following oligos were transfected for siRNA-mediated knockdown:
AllStars Negative Control siRNA (1027281, Qiagen); Hs_ATF4_9 Flexi-
Tube siRNA (SI04236337, Qiagen); Hs_IKBKE_6 FlexiTube siRNA,
(S102622319, Qiagen); Hs_IKBKE_7 FlexiTube siRNA (S102622326,
Qiagen); Hs_IKBKE_8 FlexiTube siRNA (S102655317, Qiagen);
Hs_IKBKE_9 FlexiTube siRNA (s102655324, Qiagen); Hs_IRF3_4 Flexi-
Tube siRNA (SI02626526, Qiagen); Hs_PSAT1_10 FlexiTube siRNA
(SI03019709, Qiagen, UK); Hs_PSAT1_12 FlexiTube siRNA (SI032
22142, Qiagen, UK); Hs_PSAT1_14 FlexiTube siRNA (SI04265625,
Qiagen, UK); Hs_PSAT1_15 FlexiTube siRNA (SI04272212, Qiagen,
UK); Hs_RELA_5 FlexiTube siRNA (SI00301672, Qiagen).
For transfection, siRNA was mixed with Dharmafect 4 (T200402,
Dharmacon), and cells were transfected according to the transfec-
tion reagent manufacturer’s instruction for 48 h or 72 h prior to
measurements. Cells were transfected with a final concentration of
50 nM siRNA, and a pool of all 4 IKBKE-targeting oligos was used
for suppression of IKKe, a pool of all 4 PSAT1-targeting oligos was
used for suppression of PSAT1, and single targeting oligos were
used for the suppression of ATF4, p65 and IRF3.
Oxygen consumption and extracellular acidification
rate measurements
An XF24 Extracellular or XF96e Extracellular Flux analyser (Sea-
horse Biosciences, Agilent Technologies) was used to determine the
bioenergetic profiles in breast cancer cell lines. Cells were plated in
six-well corning dishes first and then transfected with siRNA 24 h
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after plating. Twenty-four hours after transfection, cells were trypsi-
nised, counted and plated into a 24 or 96-well Seahorse plate.
Oxygen consumption rates (OCR) and extracellular acidification
rates (ECAR) were assessed in Seahorse medium according to the
manufacturer protocols. Respiratory parameters were assessed as
described in Fig EV1B. Oxygen consumption rate (OCR) of Flp-In
293 cells was measured using an Oroboros high-resolution
respirometer (Oroboros) at 37°C, in Seahorse XF assay medium
containing 4.5 g/l glucose, 1 mM pyruvate and 25 mM Hepes, and
the assay was performed as in Fig EV1B.
For measurements in isolated mitochondria, Flp-In 293 cells
were first washed with PBS and collected in homogenisation
buffer (250 mM sucrose, 5 mM Hepes, pH 7.4, 0.5 mM EGTA),
and Protease inhibitor cocktail (1187358001, Roche) and then
homogenised in a glass/glass, tight potter by 100 strokes on ice,
followed by centrifugation for 5 min at 800 g at 4°C. The super-
natant, containing mitochondria, was centrifuged again at 9,000 g.
The pellet was resuspended and adjusted to a protein concentra-
tion of 0.8 mg/ml in OCB buffer (125 mM KCl, 20 mM
MOPS, 10 mM Tris ph7.2–7.3, 0.2 mM EGTA, 2.5 mM
KH2PO4, 2.5 mM MgCl2). 10 mM glutamate and 5 mM malate
were added to the mitochondrial suspension before the experi-
ment, and OCR was measured in OCB buffer using the Oroboros
high-resolution respirometer. ADP (final concentration 0.25 mM),
Cyt.C (10 lM), oligomycin (5 lM) were injected step by step, and
50 lM FCCP was added in 1 ll steps until maximum respiratory
capacity was detected. At the end of the run, antimycin (5 lM
final concentration) was injected. Data were then analysed by the
Datalab 5.5 (Oroboros) software.
Cell proliferation assay
Cells were plated in Corning 96-well plates at a density between
2,000 and 10,000 cells per well for different cell lines. Cell prolifera-
tion rate was then measured using the IncuCyte ZOOM instrument
(Essen Biosciences) for 3–7 days, and proliferation rate was anal-
ysed with the Incucyte Zoom 2015A software (Essen Biosciences).
Metabolic labelling and metabolome analysis
Flp-In 293 cells and breast cancer cell lines (T47D and MDA-MB-
468) were first plated separately in six-well plates in five technical
replicas per each condition. IKKe expression in Flp-In 293 cells was
then induced by 50 ng/ml doxycycline, and breast cancer cells were
transfected with siRNA to suppress IKKɛ. Two hours after induction
for the Flp-In 293 cells, and 48 h after siRNA transfection for the
breast cancer cell lines, cells were incubated with either 13C6-
glucose (CLM-1396-5, Cambridge Isotope Laboratories) medium or
15N2-glutamine (NLM-1328-0.25, Cambridge Isotope Laboratories)
medium for 14 h. Cells were then washed three times with PBS, and
metabolites were extracted using cold extraction buffer (50%
methanol, 30% acetonitrile, 20% ultrapure water, 100 ng/ml
HEPES) at a ratio of 1 ml extraction buffer/106 cells. After 15-min
incubation time on methanol and dry ice, cells were placed on a
shaker for 15 min using a thermal mixer at 4°C and incubated for
1 h at 20°C. Cell lysates were centrifuged, and the supernatant
was collected and transferred into autosampler glass vials, which
were stored at 80°C until further analysis.
Samples were randomised in order to avoid bias due to machine
drift and processed blindly. LC–MS analysis was performed using a
Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer coupled
to a Dionex U3000 UHPLC system (Thermo Fisher Scientific). The
liquid chromatography system was fitted with a Sequant ZIC-pHILIC
column (150 mm × 2.1 mm) and guard column (20 mm × 2.1 mm)
from Merck Millipore and temperature maintained at 45°C. The
mobile phase was composed of 20 mM ammonium carbonate and
0.1% ammonium hydroxide in water (solvent A) and acetonitrile
(solvent B). The flow rate was set at 200 ll/min with the gradient
described previously (Mackay et al, 2015). The mass spectrometer
was operated in full MS and polarity switching mode. The acquired
spectra were analysed using Xcalibur Qual Browser and Xcalibur
Quan Browser software (Thermo Fisher Scientific).
Phosphoproteomics
Sample preparation
Flp-In 293 single cell clones for IKKɛ (Clones 1,2 and 3) and GFP
(Clones 1,2 and 3) were seeded in 6-well plate in three replica for each
condition. After 24 h of seeding, cells were induced with doxycycline
for 16 h. Cells were first washed with ice-cold PBS containing 1 mM
Na3VO4 and 1 mM NaF and then lysed in a lysis buffer containing 8M
Urea, 20 mM HEPES, 1 mM Na3VO4, 1 mM NaF, 1 mM B-Glycerol
phosphate and 0.25 mM Na2H2P2O7. After incubation on ice for
5 min, the cells were then scraped and collected in Eppendorf tubes
and stored at 80°C. For sample analysis, cell lysates were thawed,
protein digested with trypsin, and phosphopeptides were enriched
using TiO2 as described in (Wilkes & Cutillas, 2017).
Nanoflow-liquid chromatography tandem mass
spectrometry (LC–MS/MS)
Dried samples were dissolved in 0.1% TFA (0.5 lg/ll) and run in a
LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific)
connected to a nanoflow ultra-high pressure liquid chromatography
(UPLC, NanoAcquity, Waters). Peptides were separated using a
75 lm × 150 mm column (BEH130 C18, 1.7 lm Waters) using
solvent A (0.1% FA in LC–MS grade water) and solvent B (0.1% FA
in LC–MS grade ACN) as mobile phases. The UPLC settings
consisted of a sample loading flow rate of 2 ll/min for 8 min
followed by a gradient elution with starting with 5% of solvent B
and ramping up to 35% over 100 min followed by a 10-min wash at
85% B and a 15-min equilibration step at 1% B. The flow rate for
the sample run was 300 nL/min with an operating back pressure of
about 3,800 psi. Full scan survey spectra (m/z 375–1,800) were
acquired in the Orbitrap with a resolution of 30,000 at m/z 400. A
data-dependent analysis (DDA) was employed in which the five
most abundant multiply charged ions present in the survey spec-
trum were automatically mass-selected, fragmented by collision-
induced dissociation (normalised collision energy 35%) and anal-
ysed in the LTQ. Dynamic exclusion was enabled with the exclusion
list restricted to 500 entries, exclusion duration of 30 s and mass
window of 10 ppm.
Database search for peptide/protein identification and MS
data analysis
Peptide identification was by searchers against the Swiss-Prot data-
base (version 2013-2014) restricted to human entries using the
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Mascot search engine (v 2.5.0, Matrix Science). The parameters
included trypsin as digestion enzyme with up to two missed cleav-
ages permitted, carbamidomethyl (C) as a fixed modification and
Pyro-glu (N-term), Oxidation (M) and Phospho (STY) as variable
modifications. Datasets were searched with a mass tolerance of
 5 ppm and a fragment mass tolerance of  0.8 Da.
The automated programme Pescal (Cutillas & Vanhaesebroeck,
2007) was used to calculate the peak areas of the peptides identified
by the mascot search engine. Proteins were identified with at least
two peptides matched to the protein and a mascot score cut-off of
50 was used to filter false-positive detection. The resulting quantita-
tive data were parsed into Excel files for normalisation and statisti-
cal analysis. Significance was assessed by t-test of log2 transformed
data. When required, P-values were adjusted using the Benjamini–
Hochberg method. Results are shown as log2 fold IKKe over control.
Western blot
Protein levels were assessed using Western blotting. Cells were
lysed in a lysis buffer (20 mM Tris–HCl, pH 7.4, 135 mM NaCl,
1.5 mM MgCl2, 1% Triton, 10% glycerol) containing cOmplete
protease inhibitor cocktail (Roche) and, where necessary, HALT
phosphatase inhibitor cocktail (78428, Thermo Fisher Scientific).
Samples were quantified using DC protein assay kit (Bio-Rad), and
equal concentration samples were then prepared for SDS-PAGE in
loading buffer (40% Glycerol, 30% b-Mercaptoethanol, 6% SDS,
bromophenol blue). SDS-PAGE was performed using either 10 or 4–
12% NuPAGETM Bis-Tris Protein gels (Invitrogen) and resolved
protein was transferred to Immobilon-P PVDF 0.45 lm Membrane
(Merck). For immunoblotting, membranes were blocked for 1 h at
room temperature in 5% w/v skimmed milk powder (Sigma-
Aldrich) diluted in TBS-T solution (1× tris-buffered saline (TBS)
(Severn Biotech) containing 0.1% v/v TWEEN 20 (P1379, Sigma-
Aldrich)) and then incubated overnight with primary antibodies
diluted in 5% w/v milk in TBS-T at 4°C with constant agitation.
Membranes were washed a minimum of three times over 15 min in
TBS-T at room temperature before incubation with secondary anti-
bodies diluted in 5% w/v milk in TBS-T at room temperature with
constant agitation. Membranes were washed again prior to develop-
ment with PierceTM Enhanced Chemiluminescence Western Blotting
Substrate (32106, Thermo Fisher Scientific), SuperSignalTM West
Pico PLUS Chemiluminescence Substrate (34577, Thermo Fisher
Scientific) or SuperSignalTM West Femto Maximum Sensitivity
Substrate (34094, Thermo Fisher Scientific). Chemiluminescent
signal was detected using either Fuji Medical X-Ray Film (Fujifilm)
or an Amersham Imager 600UV chemiDoc system (GE Healthcare).
Primary antibodies used were as follows: Actin (sc-1615, Santa
Cruz Biotechnology); ATF4 (ab1371, Abcam); c-Myc (Y69 clone,
Abcam); HA-tag (11867423001, Roche); IKKɛ (14907, Sigma-
Aldrich); IRF3 (11904, Cell Signaling); p-IRF3 Ser396 (4947, Cell
Signaling); OAS1 (sc-98424, Santa Cruz Biotechnology); PHGDH
(HPA021241, Sigma); PSAT1 (20180-1-AP, Proteintech Europe);
PSPH (14513-1-AP, Proteintech Europe); SHMT2 (12762, Cell Signal-
ing); P65 (8242, Cell Signaling); p-P65 (3039, Cell Signaling); STAT1
(9172, Cell Signaling); p-STAT1 Tyr701 (9167, Cell Signaling);
Vinculin (66305-1-Ig, Proteintech Europe). Secondary antibodies
used were as follows: Anti-mouse IgG, HRP-linked Antibody (7076,
Cell Signaling); chicken anti-rat IgG-HRP (sc-2956, Santa Cruz
Biotechnology); donkey anti-goat IgG-HRP (sc-2020, Santa Cruz Bio
technology); goat anti-mouse IgG-HRP (sc-2005, Santa Cruz Biotech-
nology); goat anti-rabbit IgG-HRP (sc-2004, Santa Cruz Biotechnol-
ogy); Rabbit IgG-HRP Linked Whole Ab (NA934, GE Healthcare).
All Western blots were performed with a minimum of three inde-
pendent biological replicates, unless otherwise indicated in specific
figure legends.
For densitometry analysis of Western blots in Fig 5C–E and
Fig EV2D, relative protein band density was quantified using NIH’s
ImageJ software (Schneider et al, 2012). Vinculin protein band
density was initially calculated for each sample. Then, within each
cell line, the percentage of total density for control siRNA and IKKe
siRNA transfected samples was calculated. This process was
repeated to calculate relative densities for each protein of interest.
Finally, the protein of interest percentage density was divided by
the corresponding vinculin percentage density for each sample to
generate normalised relative density values.
High-content imaging and measurement of mitochondrial
membrane potential (Dwm)
Cells were seeded in thin, clear bottom black 96-well plates (BD
Falcon) at medium density (4,000 cells/well) 24 h before the experi-
ments. Prior to imaging cells were loaded with 1 lg/ml Hoechst
33342 (Sigma-Aldrich) and 30 nM tetramethyl-rhodamine-methy-
lester (TMRM) for 30 min. TMRM was present during imaging in
the solution (DMEM w/o phenol red). Images were acquired with
the ImageXpress Micro XL (Molecular Devices) high-content wide
field digital imaging system using a Lumencor SOLA light engine
illumination, ex377/50 nm em447/60 nm (Hoechst) or ex562/
40 nm and ex624/40 nm (TMRM) filters, and a 60X, S PlanFluor
ELWD 0.70 NA air objective, using laser-based autofocusing.
Sixteen fields/well were acquired. Images were analysed with the
granularity analysis module in the MetaXpress 6.2 software
(Molecular Devices) to find mitochondrial (TMRM) and nuclear
(Hoechst) objects with local thresholding. Average TMRM intensi-
ties per cell were measured and averaged for each well. The mean
of wells was then used as individual data for statistical analysis to
compare each condition.
PDH activity measurement
PDH activity was measured on whole cell lysates using the pyruvate
dehydrogenase (PDH) Enzyme Activity Microplate Assay Kit
(ab109902, Abcam).
qRT–PCR
mRNA levels were assessed using quantitative real-time PCR (qRT–
PCR). Total RNA was extracted from cells using the RNeasy Mini Kit
(Qiagen) as per the manufacturer’s protocol. RNA yield was quanti-
fied using the NanoDrop ND-1000 (Thermo Fisher Scientific), and
1 mg of RNA was reverse transcribed to cDNA using the Omniscript
RT Kit (Qiagen). qPCR was performed using the TaqManTM assay
system.
The following TaqManTM gene expression probes were used:
PHGDH (Hs00198333_m1, Thermo Fisher Scientific); PSAT1
(Hs00795278_mH, Thermo Fisher Scientific); PSPH (Hs00
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190154_m1, Thermo Fisher Scientific); ACTB (b-Actin, 4310881E,
Applied Biosystems).
Assay mixtures were prepared consisting of 10 ll TaqManTM
Master Mix (Applied Biosystems), 1 ll TaqManTM gene probe & 1 ll
cDNA, topped up to 20 ll with 8 ll RNase free H2O. The qPCR reac-
tion was carried out using either the 7500 Real Time or the QuantS-
tudio 5 Real-Time PCR systems (Applied Biosystems), and the
process was 2 min at 50°C, followed by 10 min holding at 95°C,
then 40 cycles of 15 seconds at 95°C and 1 min at 60°C. Relative
mRNA quantifications were obtained using the comparative Ct
method, and data were analysed using either the 7500 software v2.3
or QuantStudio Design & Analysis Software (Applied Biosystems).
Generation of conditioned medium
Flp-In 293 HA-GFP or HA-IKKe cells were treated for 16 h with
50 ng/ml doxycycline in 1 ml of medium per well of a 6-well plate,
allowing secretion of potential signalling factors into the medium.
Following induction, medium was collected and filtered using a
0.22 lM pore size filter and stored at 4°C till use.
Gene expression analysis of clinical samples
The METABRIC dataset (Curtis et al, 2012) was obtained
from Synapse: https://www.synapse.org/#!Synapse:syn1688369
(METABRIC Data for Use in Independent Research). All analysis
was carried out using Bioconductor R packages. Overexpression of
all genes was determined by fitting a Gaussian distribution to the
central subpopulation shifted to zero and then determining samples
which had expressions greater than 1.96 times the standard devia-
tion from zero.
Data availability
Datasets generated as part of this study through labelled metabolite
analysis and phosphoproteomic analysis are both provided in full as
part of this manuscript as Datasets EV1 and EV2, respectively.
Statistical analysis
Data are presented as mean  either standard deviation (SD) or
standard error of the mean (SEM) as indicated in the figure legends.
Statistical analysis tests were performed using GraphPad Prism (ver-
sion 8), and specific tests were performed as indicated in the figure
legends. Statistical significance was assumed at P < 0.05 and is
noted on figures using *P < 0.05, **P < 0.01, ***P < 0.001 and
****P < 0.0001 where appropriate.
Expanded View for this article is available online.
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